Results 41 to 50 of about 3,679 (147)

Clinical validation of a patient‐friendly saliva microsampling approach to monitor perampanel levels in people with epilepsy

Epilepsia, EarlyView.
Abstract Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction.
Valentina Franco, Francesca Dattrino, Michela Palmisani, Federica Tacchella, Elena Tartara, Valentina De Giorgis, Carlo Alberto Quaranta, Ludovica Pasca, Paola Rota, Emilio Russo, Andrea Romigi, Cecilie Johannessen Landmark, Guido Fedele, Cristina Tassorelli, Pierluigi Nicotera   +14 more
wiley   +1 more source

Gamma suppression correlates with thalamic stimulation therapeutic response in intractable epilepsy

Epilepsia, EarlyView.
Abstract Objective In patients with drug‐resistant epilepsy who undergo anterior nucleus of the thalamus (ANT) deep brain stimulation (DBS), efficacy is assessed months after therapy initiation and clinicians have no guidance when choosing stimulation parameters due to the lack of real‐time biomarkers.
Zachary T. Sanger, Xinbing Zhang, Thomas Lisko, Hafsa Farooqi, Steffen Ventz, Sandipan Pati, Thomas R. Henry, David P. Darrow, Michael C. Park, Theoden I. Netoff, Robert A. McGovern   +10 more
wiley   +1 more source

Intermittent fasting with medium‐chain triglycerides in drug‐resistant epilepsy: A pilot crossover trial

Epilepsia, EarlyView.
Abstract Objective Ketogenic dietary therapies can reduce seizure frequency in drug‐resistant epilepsy, but adherence to the classical ketogenic diet is often poor. Intermittent fasting supplemented with medium‐chain triglycerides (MCTs) may offer a more feasible and less restrictive alternative.
Wiebke Hahn, Emily Falk, Ayla Balzter, Tobias Foer, Shanin Maierhofer, Sophia Jaumann, Sascha Strehlau, Leona Möller, Panagiota‐Eleni Tsalouchidou, Katja Menzler, Lars Timmermann, Susanne Knake   +11 more
wiley   +1 more source

Phenobarbital use in pediatric perampanel overdose with coma, respiratory compromise

Toxicology Reports
Perampanel (Fycompa®) is a non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) glutamate receptor antagonistic antiepileptic medication used to treat generalized seizure disorders.
Adam Brzezinski, Cesar I. Menchaca, Shashikanth Gangu   +2 more
doaj   +1 more source

SUDEP and mortality in developmental and epileptic encephalopathies: A meta‐analysis of randomized clinical trials and extension studies

Epilepsia, EarlyView.
Abstract Objective Developmental and epileptic encephalopathies (DEEs) are associated with high premature mortality and increased risk of sudden unexpected death in epilepsy (SUDEP). However, epidemiological data remain limited, particularly for specific syndromes such as Dravet syndrome (DS), Lennox–Gastaut syndrome (LGS), and infantile epileptic ...
Pierludovico Moro, Maria Sole Borioni, Adolfo Mazzeo, Enrico Cocchi, Carlo Di Bonaventura, Emanuele Cerulli Irelli   +5 more
wiley   +1 more source

Lipid‐based Nano‐delivery systems as a promising strategy for the treatment of epilepsy: Current status and challenges

Epilepsia Open, EarlyView.
Abstract Objective Epilepsy is a prevalent chronic neurological disorder characterized by abnormal neuronal electrical activity. The primary treatment modality for individuals with epilepsy (PWE) is antiseizure medication (ASM). The multiple potential factors contributing to treatment resistance in epilepsy may be attributed to the inability of ASMs to
Priya Kannan Varshini, Arunachalam Divya, Kumar Sowndharya, Parthiban Jeevitha, Selvam Manoj, Ashiq Rahman, Athil Ahamed, Ravichandiran Abirahul, Paranthaman Subash, Sulekha Khute   +9 more
wiley   +1 more source

Results of the Expert Forum on the application of perampanel in routine clinical practice

Эпилепсия и пароксизмальные состояния, 2020
In February 2020, in Moscow, Expert Forum was held on the issues of the application of perampanel in routine clinical practice. The main aim of the Forum was to discuss the tolerance and safety profile of perampanel in patients with epilepsy in different
article Editorial
doaj   +1 more source

Status epilepticus: Updates on mechanisms and treatments

Epilepsia Open, EarlyView.
Abstract Status epilepticus (SE) consists of prolonged, self‐sustaining seizures and is a common neurological emergency that causes respiratory compromise and neuronal injury. Without prompt treatment, the seizures can become resistant to benzodiazepines, leading to the progressive evolution of established, refractory, and super‐refractory SE.
Suchitra Joshi, Jaideep Kapur
wiley   +1 more source

Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro

The Journal of Headache and Pain, 2018
Background Perampanel is a novel antiepileptic drug acting via non-competitive antagonism on glutamatergic AMPA receptors, and the subsequent inhibition of ion calcium influx.
Giuseppe Tringali, Diego Currò, Pierluigi Navarra   +2 more
doaj   +1 more source

Natural language processing‐based emotion and usage analysis of an AI‐powered chatbot for epilepsy support

Epilepsia Open, EarlyView.
Abstract Objective Artificial intelligence (AI)‐powered chatbots are increasingly used for patient education and mental health support, yet their effectiveness in epilepsy care remains underexplored. This study examines text‐based interactions between users and EpiloBot, an epilepsy‐focused chatbot, to understand conversational patterns and emotional ...
Keiichi Watanuki, Ryoya Oba, Naoki Nozawa, Tomoki Ishihara, Koko Oga, Takayuki Iwayama, Takafumi Shiganami, Sayaka Kobayashi, Hironori Kuga, Haruo Yoshimasu, Izumi Kuramochi   +10 more
wiley   +1 more source